Zydus receives final approval from the USFDA for Acetazolamide for Injection

Ahmedabad, 17 April, 2019

Zydus Cadila has received the final approval from the USFDA to market Acetazolamide for Injection USP (US RLD – Diamox for Injection), 500 mg per single-dose vial. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g. some types of glaucoma), treatment of certain convulsive disorders (e.g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiac edema).

The group now has 262 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***